 article. NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS0, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-000-000 and STARTRK-0) Message Subject (Your Name) has forwarded a page to you from 